Clinical Report: Identifying Patients With GA for Complement Inhibition Treatment
Overview
This case study highlights the importance of patient selection for complement inhibition therapy in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). An 86-year-old patient with documented disease progression and preserved central vision was successfully treated with an FDA-approved complement inhibitor.
Background
Expand on the mechanism of action of complement inhibitors and their impact on GA.
Data Highlights
No numerical data was provided in the case study.
Key Findings
Cross-check findings with the case study to ensure all points are accurately represented.Clinical Implications
Clinicians should utilize multimodal imaging for accurate diagnosis and monitoring of GA progression. Educating patients about the benefits and limitations of complement inhibition therapy is essential for informed decision-making.
Conclusion
This case underscores the importance of careful patient selection and the role of complement inhibitors in managing GA secondary to AMD. Ongoing monitoring and patient education remain critical components of effective treatment.
References
- Retinal Physician, 2025 -- How I Work With My Patients on Complement Inhibitor Therapy for GA
- Retinal Physician, 2024 -- Patient Selection, Treatment Options, and Beyond With Complement Cascade Inhibitors for GA
- Ophthalmology Management, 2025 -- Case Study: Preserving Vision in Geographic Atrophy with Complement Inhibitor Therapy
- Retinal Physician, 2025 -- Complement Inhibition Slows GA in Eyes With Wet AMD
- AAO Preferred Practice Pattern - University of Miami, 2025 -- AAO Preferred Practice Pattern for AMD
- ScienceDirect -- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY)
- AAO Preferred Practice Pattern - University of Miami
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials - ScienceDirect
- Visual Acuity and Quality of Life Outcomes With Pegcetacoplan Treatment: A Post Hoc Analysis From the OAKS and DERBY Trials - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.